Correspondence in April and May 2020 between the 340B prime vendor and a law firm sheds more light on the start of a policy that the federal government ended abruptly last week that let hospitals start using 340B drugs at certain offsite locations sooner than it previously would allow.
Hospitals are still reeling over the U.S. Health Resources and Services Administration decision last week to end a 340B patient eligibility policy it announced three years ago as a COVID-19 flexibility but quickly said applied regardless of the pandemic. The policy said that for hospitals unable to register outpatient facilities in 340B because they are not yet on the hospital’s most recently filed Medicare cost report, “the patients of the new site may still be 340B eligible to the extent that they are patients of the covered entity.”
Correspondence in April and May 2020 between the 340B prime vendor and a law firm sheds more light on the start of a policy that the federal government ended abruptly last week that let hospitals start using 340B drugs at […]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
